Status:
COMPLETED
A Long Term Safety Study of Degarelix in Patients With Prostate Cancer
Lead Sponsor:
Ferring Pharmaceuticals
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
PHASE3
Brief Summary
Patients that completed any of the trials; CS27 (NCT00738673), CS28 (NCT00831233), CS30 (NCT00833248) or CS31 (NCT00884273) will be given the opportunity to receive monthly doses of degarelix until th...
Eligibility Criteria
Inclusion
- Completed any of the trials; FE 200486 CS27, CS28, CS30 or CS31
Exclusion
- Discontinued any of the trials: FE 200486 CS27, CS28, CS30 or CS31
Key Trial Info
Start Date :
August 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2011
Estimated Enrollment :
77 Patients enrolled
Trial Details
Trial ID
NCT00967018
Start Date
August 1 2009
End Date
December 1 2011
Last Update
January 3 2013
Active Locations (62)
Enter a location and click search to find clinical trials sorted by distance.
1
Institut Jules Bordet
Brussels, Belgium
2
St. Elisabethziekenhuis
Turnhout, Belgium
3
Hopital Jean Minjoz
Besançon, France
4
Institut Bergonié
Bordeaux, France